Patients in all studies can consent to longitudinal data use to accelerate RWE
Patient-centric healthcare data technology provider Seqster PDM, Inc. announced a three-year partnership with Boehringer Ingelheim to use the SeqsterOS to close the Real World Evidence (RWE) gap. To that end, SeqsterOS will provide patients in all of BI's studies access and engagement with longitudinal RWD, with full patient consent and control.
Read more about the partnership.
Listen to a podcast with Seqster CEO & Co-founder Ardy Arianpour.
Phase III THARROS Trial to Evaluate Impact of Breztri Aerosphere on Cardiopulmonary Outcomes in COPD
March 14th 2024THARROS trial investigators seek to provide first-of-its-kind evidence supporting a strategy of comprehensive cardiopulmonary risk reduction with a triple therapy in patients with chronic obstructive pulmonary disease.